
|Articles|November 26, 2013
GSK and Amicus Therapeutics Revise Migalastat Agreement
Author(s)BioPharm International Editors
GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.
Advertisement
Under the terms of the revised agreement:
- Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCl co-formulated with ERT) as well as migalastat HCl monotherapy
- GSK will be eligible for future regulatory and commercial milestone payments, as well as royalty payments.
- GSK will further invest $3 million in Amicus through an equity investment in a concurrent private placement in public equity (PIPE) transaction
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement